Privacy Consent on FHIR (PCF)
1.1.1-current - ci-build International flag

Privacy Consent on FHIR (PCF), published by IHE IT Infrastructure Technical Committee. This guide is not an authorized publication; it is the continuous build for version 1.1.1-current built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IHE/ITI.PCF/ and changes regularly. See the Directory of published versions

ValueSet: clinical codes that indicate HIV (Experimental)

Official URL: https://profiles.ihe.net/ITI/PCF/ValueSet/SlsSensitiveHIV Version: 1.1.1-current
Draft as of 2025-10-07 Computable Name: SlsSensitiveHIV

HIV/AIDS information

  • SAMSHA C2S HIV/AIDS Information
    • ValueSet 2.16.840.1.113762.1.4.1142.23 // HCPCS
    • ValueSet 2.16.840.1.113762.1.4.1142.24 // ICD9CM
    • ValueSet 2.16.840.1.113762.1.4.1142.25 // LOINC
    • ValueSet 2.16.840.1.113762.1.4.1142.26 // RXNORM
    • ValueSet 2.16.840.1.113762.1.4.1142.27 // SNOMED-CT
    • ValueSet 2.16.840.1.113762.1.4.1142.60 // CPT
  • SAMSHA Test C2S HIV/AIDS Information Sensitivity
    • ValueSet 2.16.840.1.113762.1.4.1142.67 // SNOMEDCD

References

This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)

Logical Definition (CLD)

This value set includes codes based on the following rules:

 

Expansion

This value set contains 162 concepts

CodeSystemDisplay
  0575Fhttp://www.nlm.nih.gov/research/umls/hcpcsHiv rna control plan of care, documented (hiv)
  3292Fhttp://www.nlm.nih.gov/research/umls/hcpcsHiv testing ordered or documented and reviewed during the first or second prenatal visit (pre-cr)
  3490Fhttp://www.nlm.nih.gov/research/umls/hcpcsHistory of aids-defining condition (hiv)
  3491Fhttp://www.nlm.nih.gov/research/umls/hcpcsHiv indeterminate (infants of undetermined hiv status born of hiv-infected mothers) (hiv)
  3492Fhttp://www.nlm.nih.gov/research/umls/hcpcsHistory of nadir cd4+ cell count <350 cells/mm (hiv)
  3493Fhttp://www.nlm.nih.gov/research/umls/hcpcsNo history of nadir cd4+ cell count <350 cells/mmand no history of aids-defining condition (hiv)
  3494Fhttp://www.nlm.nih.gov/research/umls/hcpcsCd4+ cell count <200 cells/mm3 (hiv)
  3495Fhttp://www.nlm.nih.gov/research/umls/hcpcsCd4+ cell count 200 - 499 cells/mm3 (hiv)
  3496Fhttp://www.nlm.nih.gov/research/umls/hcpcsCd4+ cell count >=500 cells/mm3 (hiv)
  3497Fhttp://www.nlm.nih.gov/research/umls/hcpcsCd4+ cell percentage <15% (hiv)
  3498Fhttp://www.nlm.nih.gov/research/umls/hcpcsCd4+ cell percentage >/=15% (hiv)
  3500Fhttp://www.nlm.nih.gov/research/umls/hcpcsCd4+ cell count or cd4+ cell percentage documented as performed (hiv)
  3502Fhttp://www.nlm.nih.gov/research/umls/hcpcsHiv rna viral load below limits of quantification (hiv)
  3503Fhttp://www.nlm.nih.gov/research/umls/hcpcsHiv rna viral load not below limits of quantification (hiv)
  3510Fhttp://www.nlm.nih.gov/research/umls/hcpcsDocumentation that tuberculosis (tb) screening test performed and results interpreted (hiv) (ibd)
  3511Fhttp://www.nlm.nih.gov/research/umls/hcpcsChlamydia and gonorrhea screenings documented as performed (hiv)
  3512Fhttp://www.nlm.nih.gov/research/umls/hcpcsSyphilis screening documented as performed (hiv)
  3513Fhttp://www.nlm.nih.gov/research/umls/hcpcsHepatitis b screening documented as performed (hiv)
  3514Fhttp://www.nlm.nih.gov/research/umls/hcpcsHepatitis c screening documented as performed (hiv)
  3515Fhttp://www.nlm.nih.gov/research/umls/hcpcsPatient has documented immunity to hepatitis c (hiv)
  4149Fhttp://www.nlm.nih.gov/research/umls/hcpcsHepatitis b vaccine injection administered or previously received (hep-c, hiv) (ibd)
  4270Fhttp://www.nlm.nih.gov/research/umls/hcpcsPatient receiving potent antiretroviral therapy for 6 months or longer (hiv)
  4271Fhttp://www.nlm.nih.gov/research/umls/hcpcsPatient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (hiv)
  4274Fhttp://www.nlm.nih.gov/research/umls/hcpcsInfluenza immunization administered or previously received (hiv) (p-esrd)
  4276Fhttp://www.nlm.nih.gov/research/umls/hcpcsPotent antiretroviral therapy prescribed (hiv)
  4279Fhttp://www.nlm.nih.gov/research/umls/hcpcsPneumocystis jiroveci pneumonia prophylaxis prescribed (hiv)
  4280Fhttp://www.nlm.nih.gov/research/umls/hcpcsPneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low cd4+ cell count or percentage (hiv)
  4290Fhttp://www.nlm.nih.gov/research/umls/hcpcsPatient screened for injection drug use (hiv)
  4293Fhttp://www.nlm.nih.gov/research/umls/hcpcsPatient screened for high-risk sexual behavior (hiv)
  86689http://www.nlm.nih.gov/research/umls/hcpcsConfirmation test for antibody to Human T-cell lymphotropic virus (HTLV) or HIV
  86701http://www.nlm.nih.gov/research/umls/hcpcsAnalysis for antibody to HIV -1 virus
  86702http://www.nlm.nih.gov/research/umls/hcpcsAnalysis for antibody to HIV-2 virus
  86703http://www.nlm.nih.gov/research/umls/hcpcsAnalysis for antibody to HIV-1 and HIV-2 virus
  87389http://www.nlm.nih.gov/research/umls/hcpcsDetection test by immunoassay technique for HIV-1 antigen and HIV-1 and HIV-2 antibodies
  87390http://www.nlm.nih.gov/research/umls/hcpcsDetection test by immunoassay technique for HIV-1 antigen
  87391http://www.nlm.nih.gov/research/umls/hcpcsDetection test by immunoassay technique for HIV-2 antigen
  87534http://www.nlm.nih.gov/research/umls/hcpcsDetection test by nucleic acid for HIV-1 virus, direct probe technique
  87535http://www.nlm.nih.gov/research/umls/hcpcsDetection test by nucleic acid for HIV-1 virus, amplified probe technique
  87536http://www.nlm.nih.gov/research/umls/hcpcsDetection test by nucleic acid for HIV-1 virus, quantification
  87537http://www.nlm.nih.gov/research/umls/hcpcsDetection test by nucleic acid for HIV-2 virus, direct probe technique
  87538http://www.nlm.nih.gov/research/umls/hcpcsDetection test by nucleic acid for HIV-2 virus, amplified probe technique
  87539http://www.nlm.nih.gov/research/umls/hcpcsDetection test by nucleic acid for HIV-2 virus, quantification
  87900http://www.nlm.nih.gov/research/umls/hcpcsInfectious agent drug susceptibility analysis
  87901http://www.nlm.nih.gov/research/umls/hcpcsAnalysis test by nucleic acid for HIV-1 virus
  87903http://www.nlm.nih.gov/research/umls/hcpcsAnalysis test by nucleic acid for HIV-1 virus, first through 10 drugs tested
  87904http://www.nlm.nih.gov/research/umls/hcpcsAnalysis test by nucleic acid for HIV-1 virus, each additional drug tested
  87906http://www.nlm.nih.gov/research/umls/hcpcsAnalysis test by nucleic acid for HIV-1 virus, other region
  G0432http://www.nlm.nih.gov/research/umls/hcpcsInfectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening
  G0433http://www.nlm.nih.gov/research/umls/hcpcsInfectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening
  G0435http://www.nlm.nih.gov/research/umls/hcpcsInfectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening
  S3645http://www.nlm.nih.gov/research/umls/hcpcsHiv-1 antibody testing of oral mucosal transudate
  136.3http://hl7.org/fhir/sid/icd-9-cmPneumocystosis
  176.9http://hl7.org/fhir/sid/icd-9-cmKaposi's sarcoma, unspecified site
  42http://hl7.org/fhir/sid/icd-9-cmOperations on esophagus
  10901-7http://loinc.orgHIV 2 gp125 Ab [Presence] in Serum by Immunoblot
  10902-5http://loinc.orgHIV 2 gp36 Ab [Presence] in Serum by Immunoblot
  11078-3http://loinc.orgHIV 2 gp80 Ab [Presence] in Serum by Immunoblot
  11079-1http://loinc.orgHIV 2 p26 Ab [Presence] in Serum by Immunoblot
  11080-9http://loinc.orgHIV 2 p53 Ab [Presence] in Serum by Immunoblot
  11081-7http://loinc.orgHIV 2 p56 Ab [Presence] in Serum by Immunoblot
  11082-5http://loinc.orgHIV 2 p68 Ab [Presence] in Serum by Immunoblot
  13920-4http://loinc.orgHIV 2 p41 Ab [Presence] in Serum by Immunoblot
  21334-8http://loinc.orgHIV 2 gp105 Ab [Presence] in Serum by Immunoblot
  21335-5http://loinc.orgHIV 2 gp120 Ab [Presence] in Serum by Immunoblot
  21336-3http://loinc.orgHIV 2 gp15 Ab [Presence] in Serum by Immunoblot
  21337-1http://loinc.orgHIV 2 gp34 Ab [Presence] in Serum by Immunoblot
  21338-9http://loinc.orgHIV 2 p31 Ab [Presence] in Serum by Immunoblot
  21339-7http://loinc.orgHIV 2 p55 Ab [Presence] in Serum by Immunoblot
  21340-5http://loinc.orgHIV 2 p58 Ab [Presence] in Serum by Immunoblot
  22358-6http://loinc.orgHIV 2 Ab [Units/volume] in Serum
  25841-8http://loinc.orgHIV 2 proviral DNA [Presence] in Blood by NAA with probe detection
  25842-6http://loinc.orgHIV 2 proviral DNA [Presence] in Specimen by NAA with probe detection
  30361-0http://loinc.orgHIV 2 Ab [Presence] in Serum or Plasma by Immunoassay
  31073-0http://loinc.orgHIV 2 Ab band pattern [Interpretation] in Serum by Immunoblot
  33806-1http://loinc.orgHIV 2 IgG Ab [Presence] in Serum by Immunoblot
  33807-9http://loinc.orgHIV 2 IgG Ab [Presence] in Serum
  34699-9http://loinc.orgHIV 2 proviral DNA [Presence] in Serum or Plasma by NAA with probe detection
  42768-2http://loinc.orgHIV 1 and 2 Ab [Interpretation] in Serum Narrative
  43185-8http://loinc.orgHIV 1 and 2 Ab band pattern [Interpretation] in Serum by Immunoblot
  45212-8http://loinc.orgHIV 2 p31+p34 Ab [Presence] in Serum by Immunoblot
  47029-4http://loinc.orgHIV 2 Ab [Presence] in Cerebral spinal fluid by Immunoblot
  51786-2http://loinc.orgHIV 2 Ab Signal/Cutoff in Serum or Plasma by Immunoassay
  5224-1http://loinc.orgHIV 2 Ab [Units/volume] in Serum or Plasma by Immunoassay
  5225-8http://loinc.orgHIV 2 Ab [Presence] in Serum by Immunoblot
  56888-1http://loinc.orgHIV 1+2 Ab+HIV1 p24 Ag [Presence] in Serum or Plasma by Immunoassay
  57976-3http://loinc.orgHIV 2 gp140 Ab [Presence] in Serum by Immunoblot
  57977-1http://loinc.orgHIV 2 p16 Ab [Presence] in Serum by Immunoblot
  57978-9http://loinc.orgHIV 2 p34 Ab [Presence] in Serum by Immunoblot
  58900-2http://loinc.orgHIV 1+2 Ab+HIV1 p24 Ag [Units/volume] in Serum or Plasma by Immunoassay
  62456-9http://loinc.orgHIV 2 p15 Ab [Presence] in Serum by Immunoblot
  6429-5http://loinc.orgHIV identified in Blood by Organism specific culture
  6430-3http://loinc.orgHIV identified in Semen by Organism specific culture
  6431-1http://loinc.orgHIV identified in Specimen by Organism specific culture
  69353-1http://loinc.orgHIV 2 RNA [Presence] in Serum or Plasma by NAA with probe detection
  69354-9http://loinc.orgHIV 2 RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
  69668-2http://loinc.orgHIV 1 and 2 Ab [Identifier] in Serum or Plasma by Rapid immunoassay
  7919-4http://loinc.orgHIV 2 Ab [Presence] in Serum
  9836-8http://loinc.orgHIV proviral DNA [Presence] in Blood by Probe with amplification
  LP14307-0http://loinc.orgHIV 1
  LP16715-2http://loinc.orgHIV 1+2
  LP16716-0http://loinc.orgHIV 2
  LP29063-2http://loinc.orgHIV reverse transcriptase gene
  LP30901-0http://loinc.orgHIV protease gene
  LP32723-6http://loinc.orgHIV reverse transcriptase+protease gene
  LP36650-7http://loinc.orgHIV 1 & 2
  LP36876-8http://loinc.orgHIV nucleoside reverse transcriptase gene
  LP36877-6http://loinc.orgHIV nonnucleoside reverse transcriptase gene
  LP38420-3http://loinc.orgHIV identified
  LP38459-1http://loinc.orgHIV 1+2 Ab
  LP38463-3http://loinc.orgHIV 2 Ab
  LP62411-1http://loinc.orgHIV 1+O+2 Ab
  152535http://www.nlm.nih.gov/research/umls/rxnormZovirax
  281http://www.nlm.nih.gov/research/umls/rxnormacyclovir
  111880001http://snomed.info/sctAcute human immunodeficiency virus infection (disorder)
  420721002http://snomed.info/sctAcquired immunodeficiency syndrome-associated disorder (disorder)
  0575Fhttp://www.ama-assn.org/go/cptHIV RNA control plan of care, documented (HIV)
  3292Fhttp://www.ama-assn.org/go/cptHIV testing ordered or documented and reviewed during the first or second prenatal visit (Pre-Cr)
  3490Fhttp://www.ama-assn.org/go/cptHistory of AIDS-defining condition (HIV)
  3491Fhttp://www.ama-assn.org/go/cptHIV indeterminate (infants of undetermined HIV status born of HIV-infected mothers) (HIV)
  3492Fhttp://www.ama-assn.org/go/cptHistory of nadir CD4+ cell count <350 cells/mm3 (HIV)
  3493Fhttp://www.ama-assn.org/go/cptNo history of nadir CD4+ cell count <350 cells/mm3 and no history of AIDS-defining condition (HIV)
  3494Fhttp://www.ama-assn.org/go/cptCD4+ cell count <200 cells/mm3 (HIV)
  3495Fhttp://www.ama-assn.org/go/cptCD4+ cell count 200 - 499 cells/mm3 (HIV)
  3496Fhttp://www.ama-assn.org/go/cptCD4+ cell count >/=500 cells/mm3 (HIV)
  3497Fhttp://www.ama-assn.org/go/cptCD4+ cell percentage <15% (HIV)
  3498Fhttp://www.ama-assn.org/go/cptCD4+ cell percentage >/=15% (HIV)
  3500Fhttp://www.ama-assn.org/go/cptCD4+ cell count or CD4+ cell percentage documented as performed (HIV)
  3502Fhttp://www.ama-assn.org/go/cptHIV RNA viral load below limits of quantification (HIV)
  3503Fhttp://www.ama-assn.org/go/cptHIV RNA viral load not below limits of quantification (HIV)
  3510Fhttp://www.ama-assn.org/go/cptDocumentation that tuberculosis (TB) screening test performed and results interpreted (HIV) (IBD)
  3511Fhttp://www.ama-assn.org/go/cptChlamydia and gonorrhea screenings documented as performed (HIV)
  3512Fhttp://www.ama-assn.org/go/cptSyphilis screening documented as performed (HIV)
  3513Fhttp://www.ama-assn.org/go/cptHepatitis B screening documented as performed (HIV)
  3514Fhttp://www.ama-assn.org/go/cptHepatitis C screening documented as performed (HIV)
  3515Fhttp://www.ama-assn.org/go/cptPatient has documented immunity to Hepatitis C (HIV)
  4149Fhttp://www.ama-assn.org/go/cptHepatitis B vaccine injection administered or previously received (HEP-C, HIV) (IBD)
  4270Fhttp://www.ama-assn.org/go/cptPatient receiving potent antiretroviral therapy for 6 months or longer (HIV)
  4271Fhttp://www.ama-assn.org/go/cptPatient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (HIV)
  4274Fhttp://www.ama-assn.org/go/cptInfluenza immunization administered or previously received (HIV) (P-ESRD)
  4276Fhttp://www.ama-assn.org/go/cptPotent antiretroviral therapy prescribed (HIV)
  4279Fhttp://www.ama-assn.org/go/cptPneumocystis jiroveci pneumonia prophylaxis prescribed (HIV)
  4280Fhttp://www.ama-assn.org/go/cptPneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low CD4+ cell count or percentage (HIV)
  4290Fhttp://www.ama-assn.org/go/cptPatient screened for injection drug use (HIV)
  4293Fhttp://www.ama-assn.org/go/cptPatient screened for high-risk sexual behavior (HIV)
  86689http://www.ama-assn.org/go/cptAntibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)
  86701http://www.ama-assn.org/go/cptAntibody; HIV-1
  86702http://www.ama-assn.org/go/cptAntibody; HIV-2
  86703http://www.ama-assn.org/go/cptAntibody; HIV-1 and HIV-2, single result
  87389http://www.ama-assn.org/go/cptInfectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result
  87390http://www.ama-assn.org/go/cptInfectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1
  87391http://www.ama-assn.org/go/cptInfectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-2
  87534http://www.ama-assn.org/go/cptInfectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique
  87535http://www.ama-assn.org/go/cptInfectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed
  87536http://www.ama-assn.org/go/cptInfectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed
  87537http://www.ama-assn.org/go/cptInfectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique
  87538http://www.ama-assn.org/go/cptInfectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed
  87539http://www.ama-assn.org/go/cptInfectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed
  87900http://www.ama-assn.org/go/cptInfectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics
  87901http://www.ama-assn.org/go/cptInfectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions
  87903http://www.ama-assn.org/go/cptInfectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested
  87904http://www.ama-assn.org/go/cptInfectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; each additional drug tested (List separately in addition to code for primary procedure)
  87906http://www.ama-assn.org/go/cptInfectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion)

Explanation of the columns that may appear on this page:

Level A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance)
Display The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code

History

DateActionAuthorVerifierComment
2023-01-31reviseJohn MoehrkeAdministrative touchup to add history
2022-07-27createJohn MoehrkeJohn F. MoehrkeInitial ValueSet as per the C2S layout